Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

  • Revenue in GBP (TTM)33.33bn
  • Net income in GBP4.31bn
  • Incorporated1999
  • Employees94.07k
  • Location
    GlaxoSmithKline PLCG S K House, 980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
UCB SA4.68bn793.83m16.01bn8.41k20.362.3914.693.424.774.7928.0240.630.42031.594.99656,082.807.166.928.838.8075.1973.5617.0415.800.858217.860.213532.068.836.65-7.3422.6319.04-4.17
Eurofins Scientific SE5.42bn905.01m18.40bn49.07k21.275.3014.233.405.314.1131.8021.320.762830.455.62123,994.5013.176.2816.358.0230.1721.2517.2710.131.2814.400.392514.7619.2022.77116.4338.2016.0236.22
Lonza Group AG3.23bn418.17m44.25bn14.41k106.097.4754.7813.686.889.5253.2597.830.2732----240,386.903.555.124.326.3541.9538.9513.0013.11--26.490.331933.197.153.4612.8321.3929.815.31
GlaxoSmithKline plc33.33bn4.31bn76.73bn94.07k17.874.9710.902.300.85360.85366.603.070.41761.694.29354,
Sanofi SA32.65bn5.24bn91.74bn99.41k17.40--13.942.814.924.9230.71--------387,237.00--4.98--5.9768.2668.1316.1214.73--29.35--69.80-0.69621.40323.6022.79-5.281.78
AstraZeneca plc24.65bn1.11bn129.62bn76.10k87.894.3426.405.260.9520.95218.1119.270.38311.334.71323,959.901.713.882.315.4671.2080.974.4710.190.68352.410.4443141.039.161.50139.402.50-1.340.2156
Novo Nordisk A/S15.35bn5.27bn144.67bn46.98k35.8024.6024.639.4219.9919.9958.2429.100.85731.254.973,009,749.0029.4135.3059.6967.1882.8984.1034.3133.510.8187--0.172250.324.043.308.183.8728.087.29
Data as of Nov 30 2021. Currency figures normalised to GlaxoSmithKline PLC's reporting currency: UK Pound GBX

Institutional shareholders

17.72%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Nov 2021152.00m3.02%
BlackRock Fund Advisorsas of 03 Mar 2021131.21m2.61%
Norges Bank Investment Managementas of 01 Nov 2021117.65m2.34%
Dodge & Coxas of 03 Mar 202199.38m1.98%
Capital Research & Management Co. (Global Investors)as of 01 Nov 202175.94m1.51%
BlackRock Advisors (UK) Ltd.as of 01 Nov 202168.79m1.37%
State Street Global Advisors Ltd.as of 01 Nov 202165.87m1.31%
Schroder Investment Management Ltd.as of 01 Nov 202165.05m1.29%
Threadneedle Asset Management Ltd.as of 01 Nov 202158.78m1.17%
Silchester International Investors LLPas of 01 Nov 202156.97m1.13%
More ▼
Data from 31 Dec 2020 - 24 Nov 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.